Internship

Quality Assurance Summer Intern

Posted on 12/20/2024

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulators for medical conditions

Biotechnology
Healthcare

Compensation Overview

$25 - $31Hourly

No H1B Sponsorship

San Carlos, CA, USA

Must work at the Redwood City office for the duration of the internship, no relocation available.

Category
QA & Testing
Quality Assurance
Required Skills
PowerPoint/Keynote/Slides
Requirements
  • Exceptional interpersonal skills and proven track record of teamwork, innovation, and initiative
  • Strong organizational skills
  • Capacity to quickly identify problems and create solutions
  • Highly effective in communicating in written, verbal, and presentation forms
  • Knowledge of Microsoft Office programs (i.e., Word, Excel, PowerPoint)
  • Passion for learning and ideally pursuing a career in the health care, biotech, pharmaceutical, or life sciences industries
  • Must be able to complete at least 10 consecutive weeks between June and August and it is a full-time internship (40 hours per week)
  • Must be able to work at our Redwood City office for the duration of the internship, no relocation available
  • Pursuing an associate’s or bachelor's degree
Responsibilities
  • Projects could include reviewing, organizing, and digesting complex information and documentation ranging from chemical manufacturing specifications to clinical study reports
  • Shadow QA team members in their work, including attending meetings ranging from simple weekly huddles to high-level strategy sessions
  • Contribute to Corcept’s preparation for regulatory inspections in support of new products
  • Deliver a department presentation at the end of the program
  • Participate as a member of the 2025 intern team group project that includes a company-wide presentation

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Company Stage

IPO

Total Funding

$42.6M

Headquarters

Menlo Park, California

Founded

1998

Growth & Insights
Headcount

6 month growth

23%

1 year growth

31%

2 year growth

49%
Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in cortisol modulation for mental health expands Corcept's market potential.
  • Advancements in biomarker discovery enhance the effectiveness of Corcept's treatments.
  • The rise of personalized medicine offers opportunities for targeted therapies by Corcept.

What critics are saying

  • Teva's antitrust lawsuit could lead to significant legal expenses for Corcept.
  • Roberto Vieira's appointment may divert resources from Corcept's core focus on cortisol.
  • Recent stock offering may dilute shareholder value, indicating potential financial challenges.

What makes Corcept Therapeutics unique

  • Corcept specializes in cortisol modulation, a niche with few direct competitors.
  • Their flagship product, Korlym, is the first FDA-approved treatment for Cushing's syndrome.
  • Corcept has discovered over 1,000 selective cortisol modulators, showcasing strong R&D capabilities.

Help us improve and share your feedback! Did you find this helpful?